Amoy Diagnostics Co

Amoy Diagnostics Co Net Margin

The Net Profit Margin of Amoy Diagnostics Co (300685.SZ) as of Oct 27, 2026 is 29.88 %. In the previous year, Net Profit Margin was 22.98 % — a change of 30.02% (higher).

Net Margin

29.88 %

YoY

30.02%

Last updated:

Net Profit Margin of Amoy Diagnostics Co is 2025 29.88 % . Net Profit Margin of Amoy Diagnostics Co was 2024 22.98 % . It decreases by 30.02% higher compared to the previous year.

For Amoy Diagnostics Co, the net margin of 29.9% is up versus 26.1% a few years ago.

The Amoy Diagnostics Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
28.87 CNY
Jan 1, 2019
23.42 CNY
Jan 1, 2020
24.76 CNY
Jan 1, 2021
26.12 CNY
Jan 1, 2022
31.32 CNY
Jan 1, 2023
25.06 CNY
Jan 1, 2024
22.98 CNY
Jan 1, 2025
29.88 CNY
The Amoy Diagnostics Co Net Margin history
YEARNet MarginYoY
29.88 %+30.02%
22.98 %-8.28%
25.06 %-19.98%
31.32 %+19.87%
26.12 %+5.53%
24.76 %+5.69%
23.42 %-18.86%
28.87 %+1.39%
28.47 %+7.46%
26.50 %+122.28%
11.92 %-33.47%
17.92 %+5,944.27%
0.30 %+41.85%
0.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amoy Diagnostics Co Stock analysis

What does Amoy Diagnostics Co do? Amoy Diagnostics Co., Ltd. generates revenue through the sale of tumor precision molecular diagnostic products, including ADx-ARMS, Super-ARMS, NGS, and FISH testing reagents. These reagents are used for detecting non-small cell lung cancer, colorectal cancer, thyroid cancer, and melanoma in tumor tissue specimens and liquid biopsies. The company also offers data software for gene sequencing data analysis and provides testing services via its medical testing institutions for lung cancer, colorectal cancer, and breast cancer. Revenue streams include reagent sales, software licensing, and diagnostic testing services. The primary customers are medical institutions and healthcare providers requiring tumor molecular diagnostics. The ADx-ARMS product line targets tumor tissue specimen detection, while Super-ARMS serves liquid biopsy applications. NGS and FISH products support comprehensive tumor genetic analysis. Testing services focus on lung, colorectal, and breast cancer diagnostics, catering to hospitals and clinics specializing in oncology. The company’s offerings align with the demand for precise cancer diagnosis and treatment planning. Amoy Diagnostics’ revenue model combines product sales with service-based offerings. Reagent products like ADx-ARMS and Super-ARMS are sold to medical facilities for routine tumor testing. Data software for gene sequencing analysis is licensed to research institutions and hospitals. Testing services through its medical testing institutions provide direct diagnostic solutions for specific cancers, enhancing customer retention through integrated service packages. Amoy Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amoy Diagnostics Co stock

Net Profit Margin of Amoy Diagnostics Co is 29.88 % in 2025.

Net Profit Margin of Amoy Diagnostics Co changed from 22.98 % to 29.88 %, representing a 30.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Amoy Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Amoy Diagnostics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Amoy Diagnostics Co

All Key Metrics — Amoy Diagnostics Co